RepRisk has released the sixth edition of its Insight e-Zine, which focuses on environmental, social and governance (ESG) matters specific to the pharmaceutical industry.
Pharmaceutical companies hold a vast amount of power and, arguably, responsibility, due to the impact they have on people’s lives. The complexity of balancing this unique position with the necessity to maintain a profitable business has produced some interesting ethical challenges.
RepRisk has released the sixth edition of its Insight e-Zine, which focuses on environmental, social and governance (ESG) matters specific to the pharmaceutical industry.
Pharmaceutical companies hold a vast amount of power and, arguably, responsibility, due to the impact they have on people’s lives. The complexity of balancing this unique position with the necessity to maintain a profitable business has produced some interesting ethical challenges.
The corresponding ESG concerns are analysed and discussed in this issue of Insight from a range of corporate, NGO and academic perspectives.
The articles cover global issues such as the ethics of clinical trials in developing countries, misleading marketing of drugs, access to medicines, balancing profitability with patient protection, water security risks, anti-competition and bribery, and more.
Click here to read the e-Zine: RepRisk Insight #6
